Anderson CM, Lee CM, Saunders DP, et al. Phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer. J Clin Oncol. 2019;37:3256-3265.
Anderson CM, Lee CM, Saunders D, et al. Tumor outcomes of phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer. Presented at: Multidisciplinary Head and Neck Cancer Symposium, February 27-29, 2020.
Anderson CM, Sonis ST, Lee CM, et al. Phase 1b/2 trial of the superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavity or oropharyngeal carcinoma. Int J Radiation Oncol Biol Phys. 2018;100:427-435.
Sishc BJ, Ding L, Nam T-K, et al. Avasopasem manganese synergizes with hypofractionated radiation to ablate tumors through the generation of hydrogen peroxide. Sci Transl Med 2021;13:eabb3768.
Hoffe SE, Frakes J, Aguilera TA, et al. Randomized, double-blinded, placebo-controlled multicenter adaptive phase 1-2 trial of GC4419, a dismutase mimetic, in combination with high dose stereotactic body radiation therapy (SBRT) in locally advanced pancreatic cancer (PC). Presented at: ASTRO Annual Meeting, October 25-28, 2020
Investigational Drugs – Not for Commercial Distribution